Report on 200 thousand cancer patients’ survival from a hospital-based cancer registry database

周昌明; 莫　淼; 袁　晶; 沈　洁; 王泽洲; 张志红; 朱　骥; 秦一雨; 郑　莹; 吴　炅; 郭小毛

doi:10.19401/j.cnki.1007-3639.2020.01.002

您当前的位置：

首页 >

文章列表页 >

Report on 200 thousand cancer patients’ survival from a hospital-based cancer registry database

更新时间：2026-01-27

- Report on 200 thousand cancer patients’ survival from a hospital-based cancer registry database
- China Oncology Vol. 30, Issue 1, Pages: 11-24(2020)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院肿瘤预防部，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学附属肿瘤医院肿瘤放疗科，复旦大学上海医学院肿瘤学系,上海,200032
  3. 上海众访信息技术有限公司,上海,200092
  4. 复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.01.002
  CLC： R73-31
- Published Online：17 January 2020，
  
  Published：17 January 2020
- 稿件说明：
移动端阅览
周昌明, 莫　淼, 袁　晶, 沈　洁, 王泽洲, 张志红, 朱　骥, 秦一雨, 郑　莹, 吴　炅, 郭小毛 . 以医院登记为基础的20万例恶性肿瘤患者生存报告[J]. 中国癌症杂志, 2020, 30(1): 11-24.

周昌明, 莫　淼, 袁　晶, et al. Report on 200 thousand cancer patients’ survival from a hospital-based cancer registry database[J]. China Oncology, 2020, 30(1): 11-24.
周昌明, 莫　淼, 袁　晶, 沈　洁, 王泽洲, 张志红, 朱　骥, 秦一雨, 郑　莹, 吴　炅, 郭小毛 . 以医院登记为基础的20万例恶性肿瘤患者生存报告[J]. 中国癌症杂志, 2020, 30(1): 11-24. DOI： 10.19401/j.cnki.1007-3639.2020.01.002.

周昌明, 莫　淼, 袁　晶, et al. Report on 200 thousand cancer patients’ survival from a hospital-based cancer registry database[J]. China Oncology, 2020, 30(1): 11-24. DOI： 10.19401/j.cnki.1007-3639.2020.01.002.

摘要

背景与目的：恶性肿瘤是全球重大的公共健康问题，患者生存率是评价恶性肿瘤诊治水平的重要指标。通过描述以医院登记为基础的20万例恶性肿瘤患者的生存情况，以真实世界数据从一个侧面反映我国恶性肿瘤的治疗效果。方法：纳入2008年1月1日—2017年12月31日之间在复旦大学附属肿瘤医院确诊为恶性肿瘤并接受住院治疗的患者共计202 542例。通过患者复诊病史资料、电话随访及死因数据链接等方式收集生存随访信息，随访统计时间截至2019年11月30日。应用寿命表法估计各个病种1年、3年和5年总生存率（overall survival，OS），以性别、年龄组、首次治疗时间分层。采用Kaplan-Meier生存曲线绘制各病种的总体生存曲线。结果：患者总体的1年、3年、5年OS分别为89.8%、77.4%和71.0%；男性患者5年OS为58.8%，女性患者为78.7%。在常见的恶性肿瘤中，甲状腺癌患者的5年OS最高，为98.6%；胰腺癌患者最低，为11.4%。2013—2017年首次治疗的乳腺癌、肺癌和肾癌患者5年OS分别为90.0%、55.9%和80.7%，显著高于2008—2012年首次治疗患者，其他肿瘤未见显著上升。结论：大部分恶性肿瘤患者经规范诊治可以获得较为理想的预后，女性生存情况显著优于男性，乳腺癌和肺癌患者的生存改善可能归功于新的临床治疗和早诊手段。

Abstract

Background and purpose: Cancer is a global major public health concern

and survival rate is a key indicator in evaluating the treatment effect of cancer. This study described the survival of over 200 thousand cancer patients from a hospital-based cancer registry database

aiming to reflect current cancer treatment effect somehow with real world data. Methods: A total of 202 542 hospitalized patients in Fudan University Shanghai Cancer Center from Jan. 1 2008 to Dec. 31 2017 were included in the analysis. Medical records review

telephone visits and death registry data linkage were applied in collecting endpoint data. The last follow-up date was Nov. 30 2019. Life table was applied in evaluating the 1-year

3-year and 5-year overall survival (OS) rate for all and stratified by gender

age group and periods. Kaplan-Meier method was applied in plotting the survival curves. Results: The 1-year

3 year and 5-year OS of cancer patients were 89.8%

77.4% and 71.0%. The 5-year OS of males and females were 58.8% and 78.7% respectively. Among common cancers

thyroid cancer held the highest 5-year survival rate 98.6% while pancreatic cancer the lowest

11.4%. The 5-year survival rates of breast

lung and kidney cancer in 2013—2017 were 90.0%

55.9% and 80.7% respectively

significantly higher than those in 2008—2012. No significant improvement was observed in other cancers. Conclusion: Most cancer patients can have a relatively better prognosis after standardized treatment. The survival of female is superior to male. The improvement of the survival of breast cancer and lung cancer could be contributed to novel treatment methods and early diagnosis.

关键词

Keywords

references

Views

3788

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Metastasis patterns and survival analysis of 20 000 patients with metastasis from a hospital-based cancer registry database

Metastasis patterns and survival analysis of 572 patients with metastatic cervical cancer: a hospital-based real world study

The impact of participation status on the colorectal cancer incidence, stage and survival outcomes in the Shanghai colorectal cancer screening program

Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database

Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer

Related Author

冯小双

Jie SHEN

Xiaoshuang FENG

Hao WEN

Changming ZHOU

Miao MO

Zezhou WANG

Jing YUAN

Related Institution

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecologic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Division of Noncommunicable Diseases and Injury, Shanghai Municipal Center for Disease Control and Prevention

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

School of Public Health, Fudan University

AI问答

⁰